



PATENT
Docket No.: 20609/261 (PD 02027)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :	Jennings et al.)	Examiner:
)	To Be Assigned
Serial No. :	10/686,309)	
)	Art Unit:
Cnfrm. No. :	To Be Assigned)	To Be Assigned
)	
Filed :	October 15, 2003)	
)	
For :	METHODS FOR ASSESSMENT OF)	
	PLATELET AGGREGATION)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98


Mail Stop:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the
United States Patent and Trademark Office, the enclosed references listed on the attached
PTO-1449 form.

Respectfully submitted,

Date: March 11, 2004


Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1128
Facsimile: (585) 263-1600

R753250.1

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
3/11/04 Date	Wendy L. Barry Wendy L. Barry

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/686,309
		Filing Date	October 15, 2003
		First Named Inventor	Jennings et al.
		Art Unit	To Be Assigned
		Examiner Name	To Be Assigned
		Attorney Docket Number	20609/261 (PD 02027)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Kandzari et al., "TARGET versus GUSTO-IV: Appropriate Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes and Percutaneous Coronary Intervention," <i>Curr. Opin. Cardiol.</i> 17:332-339 (2002)	
	2	Gold et al., "Rapid and Sustained Coronary Artery Recanalization with Combined Bolus Injection of Recombinant Tissue-Type Plasminogen Activator and Monoclonal Antiplatelet GPIIb/IIIa Antibody in a Canine Preparation," <i>Circulation</i> 77:670-677 (1988)	
	3	The EPIC Investigators, "Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty," <i>N. Engl. Med.</i> 330:956-961 (1994)	
	4	Steinhubl Sr. et al., "Point-of-Care Measured Platelet Inhibition Correlates with a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention," <i>Circulation</i> 103:2572-2578 (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/686,309
				Filing Date	October 15, 2003
				First Named Inventor	Jennings et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	20609/261 (PD 02027)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5	Jennings et al., "Expression of Ligan-Induced Binding Sites on Glycoprotein IIb/IIIa Complexes and the Effect of Various Inhibitors," <i>Am. Heart J.</i> 135:S179-S183 (1998)	
	6	Kereiakes et al., "Time Course, Magnitude and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention," <i>Am. J. Cardiol.</i> 84:391-395 (1999)	
	7	Simon et al., "A Comparative Study of Light Transmission Aggregometry and Automated Bedside Platelet Function Assay in Patients Undergoing Percutaneous Coronary Intervention and Receiving Abciximab, Eptifibatide, or Tirofiban," <i>Cathet. and Cardiovasc. Intervent.</i> 52:425-432 (2001)	
	8	Phillips et al., "Effect of Ca ⁺⁺ on Integrilin TM GPIIb-IIIa Interactions: Enhanced GPIIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated with Citrate," <i>Circulation</i> 96:1488-1494 (1997)	
	9	Nannizzi-Alaimo et al., "Effect of Citrate Anticoagulation and Platelet Agonist Concentration on the Inhibitory Activities of GPIIb-IIIa Antagonists," <i>Circulation</i> 100:1710 (1999)	
	10	Kereiakes et al., "Differential Effects of Citrate Versus PPACK Anticoagulation on Measured Platelet Inhibition by Abciximab, Eptifibatide and Tirofiban," <i>J. Thromb. Thrombolysis</i> 12:123-127 (2001)	
	11	Jennings et al., "The Pharmacodynamics of Parental Glycoprotein IIb/IIIa Inhibitors," <i>J. Interv. Cardiol.</i> 15:45-60 (2002)	
	12	Wheeler et al., "The Ultegra Rapid Platelet-Function Assay: Comparison to Standard Platelet Function Assays in Patients Undergoing Percutaneous Coronary Intervention with Abciximab Therapy," <i>Am. Heart J.</i> 143:602-611 (2002)	
	13	Lakkis et al., "Use of ICHOR-Platelet Works to Assess Platelet Function in Patients Treated with GP IIb/IIIa Inhibitors," <i>Cathet. and Cardiovasc. Intervent.</i> 53:346-351 (2001)	
	14	Nannizzi-Alaimo et al., "GPIIb-IIIa Antagonists Demonstrate a Dose-Dependent Inhibition and Potentiation of Soluble CD40L (CD154) Release During Platelet Stimulation," <i>Circulation</i> 104(suppl II):II-318 (2001) (Abstract #1533)	
	15	Andre et al., "Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease," <i>Circulation</i> 106:896-899 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/686,309
				Filing Date	October 15, 2003
				First Named Inventor	Jennings et al.
				Art Unit	To Be Assigned
Examiner Name	To Be Assigned				
Sheet	1	of	2	Attorney Docket Number	20609/261 (PD 02027)

U.S. PATENT DOCUMENTS					
Examiner Initials ⁵	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁵	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ⁵	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Kandzari et al., "TARGET versus GUSTO-IV: Appropriate Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes and Percutaneous Coronary Intervention," <i>Curr. Opin. Cardiol.</i> 17:332-339 (2002)	
	2	Gold et al., "Rapid and Sustained Coronary Artery Recanalization with Combined Bolus Injection of Recombinant Tissue-Type Plasminogen Activator and Monoclonal Antiplatelet GPIIb/IIIa Antibody in a Canine Preparation," <i>Circulation</i> 77:670-677 (1988)	
	3	The EPIC Investigators, "Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty," <i>N. Engl. Med.</i> 330:956-961 (1994)	
	4	Steinhubl Sr. et al., "Point-of-Care Measured Platelet Inhibition Correlates with a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention," <i>Circulation</i> 103:2572-2578 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/686,309
				Filing Date	October 15, 2003
				First Named Inventor	Jennings et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	20609/261 (PD 02027)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	5	Jennings et al., "Expression of Ligan-Induced Binding Sites on Glycoprotein IIb/IIIa Complexes and the Effect of Various Inhibitors," <i>Am. Heart J.</i> 135:S179-S183 (1998)	
	6	Kereiakes et al., "Time Course, Magnitude and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients with Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention," <i>Am. J. Cardiol.</i> 84:391-395 (1999)	
	7	Simon et al., "A Comparative Study of Light Transmission Aggregometry and Automated Bedside Platelet Function Assay in Patients Undergoing Percutaneous Coronary Intervention and Receiving Abciximab, Eptifibatide, or Tirofiban," <i>Cathet. and Cardiovasc. Intervent.</i> 52:425-432 (2001)	
	8	Phillips et al., "Effect of Ca ⁺⁺ on Integrilin TM GPIIb-IIIa Interactions: Enhanced GPIIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated with Citrate," <i>Circulation</i> 96:1488-1494 (1997)	
	9	Nannizzi-Alaimo et al., "Effect of Citrate Anticoagulation and Platelet Agonist Concentration on the Inhibitory Activities of GPIIb-IIIa Antagonists," <i>Circulation</i> 100:1710 (1999)	
	10	Kereiakes et al., "Differential Effects of Citrate Versus PPACK Anticoagulation on Measured Platelet Inhibition by Abciximab, Eptifibatide and Tirofiban," <i>J. Thromb. Thrombolysis</i> 12:123-127 (2001)	
	11	Jennings et al., "The Pharmacodynamics of Parental Glycoprotein IIb/IIIa Inhibitors," <i>J. Interv. Cardiol.</i> 15:45-60 (2002)	
	12	Wheeler et al., "The Ultegra Rapid Platelet-Function Assay: Comparison to Standard Platelet Function Assays in Patients Undergoing Percutaneous Coronary Intervention with Abciximab Therapy," <i>Am. Heart J.</i> 143:602-611 (2002)	
	13	Lakkis et al., "Use of ICHOR-Platelet Works to Assess Platelet Function in Patients Treated with GP IIb/IIIa Inhibitors," <i>Cathet. and Cardiovasc. Intervent.</i> 53:346-351 (2001)	
	14	Nannizzi-Alaimo et al., "GPIIb-IIIa Antagonists Demonstrate a Dose-Dependent Inhibition and Potentiation of Soluble CD40L (CD154) Release During Platelet Stimulation," <i>Circulation</i> 104(suppl II):II-318 (2001) (Abstract #1533)	
	15	Andre et al., "Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease," <i>Circulation</i> 106:896-899 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.